BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23595643)

  • 1. Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.
    Amzat R; Taleghani P; Miller DL; Beitler JJ; Bellamy LM; Nye JA; Yu W; Savir-Baruch B; Osunkoya AO; Chen Z; Auffermann WF; Goodman MM; Schuster DM
    Mol Imaging Biol; 2013 Oct; 15(5):633-43. PubMed ID: 23595643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma.
    Savir-Baruch B; Schuster DM; Jarkas N; Master VA; Nieh PT; Halkar RK; Nye JA; Lewis MM; Crowe RJ; Voll RJ; Camp VM; Bellamy LM; Roberts DL; Goodman MM
    Mol Imaging Biol; 2011 Dec; 13(6):1272-7. PubMed ID: 20976627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
    Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
    J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.
    Schuster DM; Taleghani PA; Nieh PT; Master VA; Amzat R; Savir-Baruch B; Halkar RK; Fox T; Osunkoya AO; Moreno CS; Nye JA; Yu W; Fei B; Wang Z; Chen Z; Goodman MM
    Am J Nucl Med Mol Imaging; 2013; 3(1):85-96. PubMed ID: 23342303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
    Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
    J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis.
    Odewole OA; Oyenuga OA; Tade F; Savir-Baruch B; Nieh PT; Master V; Chen Z; Wang X; Jani AB; Bellamy LM; Halkar RK; Goodman MM; Schuster DM
    Mol Imaging Biol; 2015 Apr; 17(2):277-83. PubMed ID: 25281411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
    Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
    Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
    Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
    J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.
    Schuster DM; Nanni C; Fanti S; Oka S; Okudaira H; Inoue Y; Sörensen J; Owenius R; Choyke P; Turkbey B; Bogsrud TV; Bach-Gansmo T; Halkar RK; Nye JA; Odewole OA; Savir-Baruch B; Goodman MM
    J Nucl Med; 2014 Dec; 55(12):1986-92. PubMed ID: 25453047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma.
    Schuster DM; Nye JA; Nieh PT; Votaw JR; Halkar RK; Issa MM; Yu W; Sepulveda J; Zeng W; Young A; Goodman MM
    Mol Imaging Biol; 2009; 11(6):434-8. PubMed ID: 19449079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.
    Nanni C; Schiavina R; Boschi S; Ambrosini V; Pettinato C; Brunocilla E; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S11-7. PubMed ID: 23591953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design.
    Jani AB; Fox TH; Whitaker D; Schuster DM
    Clin Nucl Med; 2009 May; 34(5):279-84. PubMed ID: 19387202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings.
    Doi Y; Kanagawa M; Maya Y; Tanaka A; Oka S; Nakata N; Toyama M; Matsumoto H; Shirakami Y
    Nucl Med Biol; 2015 Aug; 42(8):664-72. PubMed ID: 26022202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients.
    Kairemo K; Rasulova N; Partanen K; Joensuu T
    Biomed Res Int; 2014; 2014():305182. PubMed ID: 24991547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats.
    Kanagawa M; Doi Y; Oka S; Kobayashi R; Nakata N; Toyama M; Shirakami Y
    Nucl Med Biol; 2014 Aug; 41(7):545-51. PubMed ID: 24816330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of
    Gusman M; Aminsharifi JA; Peacock JG; Anderson SB; Clemenshaw MN; Banks KP
    Radiographics; 2019; 39(3):822-841. PubMed ID: 31059396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.